Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab
Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab. // Seminars in Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0093775426001065?dgcid=rss_sd_all
Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Seminars in Oncology. https://www.sciencedirect.com/science/article/pii/S0093775426001065?dgcid=rss_sd_all
“Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab.” Seminars in Oncology.
@article{article65824,
title = {Early hepatic decompensation is associated with mortality in patients with HCC treated with atezolizumab plus bevacizumab or durvalumab plus tremelimumab},
journal = {Seminars in Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0093775426001065?dgcid=rss_sd_all}
}